Therapy Areas: Inflammatory Diseases
Onco3R Therapeutics receives Belgian regulatory approval for clinical trial of novel SIK3 inhibitor
5 September 2025 - Onco3R Therapeutics, a Belgium-based clinical-stage immunology and oncology biotech company, announced on Thursday the approval of a clinical trial application by the Belgian regula...
Mesoblast agrees option to issue USD50m of convertible notes
4 September 2025 - Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a developer of allogeneic cellular medicines for inflammatory diseases, announced on Wednesday that it has entered into convertible note su...
LPOXY agrees financing to fund registrational STOP-Cdiff trial
4 September 2025 - LPOXY Therapeutics Inc, a clinical-stage biopharmaceutical company developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced on Wed...
Resolution Therapeutics reports first patient dosed in Phase I/II EMERALD study
4 September 2025 - Resolution Therapeutics, a UK-based clinical-stage biopharmaceutical company involved in Regenerative Macrophage Therapy (RMT) to treat inflammatory and fibrotic diseases, announced...
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
25 August 2025 - Biotechnology company Coya Therapeutics Inc (NASDAQ: COYA) announced on Monday that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) applica...
Lighthouse Pharmaceuticals announces receipt of USD49.2m grant from NIA for LHP588 study
25 August 2025 - Lighthouse Pharmaceuticals, a clinical-stage biopharmaceutical company pioneering precision therapies for neurodegenerative diseases, announced on Friday that it has been awarded a US...